There’s Reason to Believe Tekmira Can Overcome this Safety Issue
Insights - There may be reason for investors to get comfortable with Tekmira's (TKMR) latest safety issue. Here's why.
Read nowSearch Results for tekmira
More Money! Why Tekmira is Worth Revisiting
Research - -TKMR remains an interest at PropThink despite rising 260% since coverage in January. Stock is undervalued relative to peers, has an expanding pipeline, and is … Continue Reading
Read now
Tekmira Continues to ‘Rebrand’
Research - Tekmira Pharmaceuticals (TKMR) continues to recast itself as a pipeline, product-focused company, steering away from investors’ long-time perception of the Canadian firm as a developer … Continue Reading
PremiumTekmira Raises Money
Long Ideas - Editor’s Note: A version of this commentary was sent to PropThink Premium subscribers on the morning of Thursday, October 17. On Friday the 18th, TKMR … Continue Reading
Read nowA PropThink Interview with Tekmira Pharmaceuticals
Long Ideas - On October 3, 2013, PropThink hosted an interview and investor Q&A with Tekmira Pharmaceuticals’ (TKMR) CEO Dr. Mark Murray. A recording and transcript of that … Continue Reading
Read nowOwn Tekmira for Exposure to RNAi Without Paying Alnylam’s Hefty Premium
Long Ideas - PropThink Subscribers who followed us into Tekmira (TKMR) at $4.70 in mid-April saw the stock touch a recent high of just over $6.00 early last … Continue Reading
Read nowThe Beginning of a Shift at Tekmira: From Focus on Delivery, to Therapy
Long Ideas - Tekmira’s (TKMR) story over the last few years has largely been focused on its siRNA delivery technology, lipid nanoparticles (LNPs), and the ability of the … Continue Reading
Read now